Vor Biopharma Inc’s recently made public that its Director RA CAPITAL MANAGEMENT, L.P. unloaded Company’s shares for reported $6.34 million on Oct 29 ’25. In the deal valued at $25.22 per share,251,518 shares were sold. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 804,231 shares worth roughly $10.87 million.
Then, RA CAPITAL MANAGEMENT, L.P. sold 124,311 shares, generating $3,408,230 in total proceeds. Upon selling the shares at $27.42, the Director now owns 1,055,749 shares.
Before that, RA CAPITAL MANAGEMENT, L.P. sold 24,579 shares. Vor Biopharma Inc shares valued at $617,424 were divested by the Director at a price of $25.12 per share. As a result of the transaction, RA CAPITAL MANAGEMENT, L.P. now holds 779,652 shares, worth roughly $10.54 million.
Citigroup initiated its Vor Biopharma Inc [VOR] rating to a Buy in a research note published on January 09, 2026; the price target was $50. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. JP Morgan began covering VOR with “an Overweight” recommendation on December 09, 2025.
Price Performance Review of VOR
On Monday, Vor Biopharma Inc [NASDAQ:VOR] saw its stock jump 5.79% to $13.52. Over the last five days, the stock has gained 16.15%. Vor Biopharma Inc shares have fallen nearly -59.28% since the year began. Nevertheless, the stocks have risen 3.36% over the past one year.
How much short interest is there in Vor Biopharma Inc?
A steep rise in short interest was recorded in Vor Biopharma Inc stocks on 2025-12-15, growing by 1.65 million shares to a total of 1.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 0.29 million shares. There was a rise of 84.84%, which implies that there is a positive sentiment for the stock.
